“A core principle of Affimed is to create value that is sustainable and to act in a manner that considers the environment and is beneficial for patients, employees and other stakeholders."
Dr. Thomas Hecht
Chairman of the Supervisory Board
Driven by our passion to understand how cancer works, we strive to revolutionize cancer treatment. It’s like putting together the pieces of a puzzle and feeling an incredible sense of joy when the picture starts to come together to benefit our patients. By harnessing the power of science, our expertise and tireless commitment to serve patients, we believe we can tackle some of the world’s biggest challenges and build a healthy future for people, society, and the planet.
To fulfil our mission, it is essential, that we perform our activities in the most responsible way. We’re aware of how responsible action positively impacts our colleagues, our community, and people worldwide. We believe that our culture and values are at the core of who we are as a company and play a critical role in our ability to achieve our mission of developing life-changing cancer immunotherapies.
We trust that our biggest potential sustainability impact lies at the core of what we do. Cancer is a devastating illness that affects not just the patient but also family, friends, and colleagues. We are committed to making a meaningful impact on the lives of cancer patients and their loved ones. We believe that we are at the forefront of the revolution in cancer treatment and are dedicated to advancing our pipeline of clinical stage programs, unlocking new possibilities for patients. Our ability to help patients fight cancer has the potential to have an outstanding impact on public health.
We recognize the importance of incorporating environmental, social and governance (ESG) considerations into our business operations and the need for successful management and long-term value creation.
In our first Sustainability Report 2022 we would like to inform our shareholders and other stakeholders, how we are anchoring responsibility in all our business activities. For our stakeholders this Report offers a first impression of our wider responsibility. It reflects our unwavering commitment to sustainability and our efforts to make a positive impact on patients, the environment, and our communities. We chose to publish our Sustainability Report with reference to the 2021 reporting standards of the Global Reporting Initiative (GRI).
We recognize the importance of incorporating environmental, social and governance (ESG) considerations into our business operations and the need for successful management and long-term value creation. Our sustainability performance is regularly assessed by ESG rating agencies. We are happy to receive valuable external feedback which we can use for continuous improvement.
On the 19th of June 2023, Affimed was awarded Prime Status in the sustainability rating carried out by Institutional Shareholder Services Inc. (ISS), a leading global proxy advisory firm. This status is awarded only to companies that fulfil demanding criteria and achieve a high sustainability performance. With this rating, Affimed is amongst the top life science companies rated by ISS. The rating is based on numerous elements that relate to different aspects of the environment, social issues and corporate governance. ISS ESG’s scientifically based rating concept places a clear, sector-specific focus on the materiality of non-financial information. It is constantly reviewed and developed to cover all relevant environmental, social and governance related topics.
If you have any questions, send us a message. We will be happy to get in touch with you.
Susanne Spieler, VP, General Counsel & Compliance Officer
Polya Ivanova, Senior Legal Counsel
Phone: +49 (0)621 56003-888